Aerie Pharmaceuticals Announces Presentations at the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, Colorado, May 1-4, 2022

Rhea-AI Summary

Aerie Pharmaceuticals (AERI) announced the presentation of fourteen abstracts at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from May 1-4, 2022, in Denver, Colorado. These abstracts pertain to Aerie's Rhopressa^®/netarsudil, AR-15512, and the "ROCK’Sters" program. Notable highlights include data from independent studies on netarsudil's real-world applications, preclinical results extending potential uses, and the Phase 2b study results for AR-15512 focusing on dry eye symptoms. Aerie aims to expand the clinical utility of its innovative treatments for ocular conditions.

Positive

• Presentation of fourteen abstracts at ARVO indicates strong ongoing research and development activity.
• Positive Phase 2b study results for AR-15512 could support future marketing and funding opportunities.
• Potential expansion of indications for netarsudil through new research adds credibility to the product line.

Negative

• None.

Abstracts showcase Rhopressa^®/netarsudil, AR-15512 and “ROCK’Ster”

DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that fourteen abstracts related to Aerie’s Rhopressa^®/netarsudil, AR-15512 in dry eye and “ROCK’Sters” anti-inflammatory programs will be presented at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2022) in Denver, Colorado, May 1 through 4, 2022.

Gary Sternberg, M.D., Chief Medical Officer at Aerie commented, "Aerie is pleased to have fourteen scientific presentations, which include Aerie-sponsored studies, investigator-initiated studies and independent research, related to clinical and preclinical data on our innovative product and product candidates being presented at the ARVO meeting in Denver, Colorado.

Dr. Sternberg continued, “The ten presentations, including independent research, related to netarsudil will add to the real-world use and experience in a range of clinical settings and patient populations. Preclinical netarsudil studies will also elaborate on the breadth of potential clinical applications for rho-kinase inhibition in other ocular indications. With the initiation of the Phase 3 trial for AR-15512 on track for the second quarter of 2022, we will be presenting and highlighting the Phase 2b study results for AR-15512 across multiple signs and symptoms in dry eye.”

Dr. Sternberg concluded, “Additionally, we are pleased to showcase preclinical abstracts related to our “ROCK’Sters” ocular anti-inflammatory program, a VEGF challenge model in miniature swine, and a novel Aerie compound showing meaningful pharmacodynamic effects in a murine meibomian gland dysfunction model.”

Aerie Sponsored Research Presentations:
Title: Dry eye sign, symptom and quality of life improvements associated with administration of AR-15512: May 2^nd (Poster)
Title: ROCK’Sters, a novel compound class combining Rho kinase inhibition with corticosteroid anti-inflammatory activity for the treatment of ocular inflammatory disease: May 2^nd (Poster)
Title: Ocular PK/PD of a Novel Non-Steroidal Anti-Inflammatory Compound on a Murine Model of Meibomian Gland Dysfunction: May 2^nd (Poster)
Title: Model development of VEGF challenge in miniature swine: May 2^nd (Poster)

Presentation of Investigator Initiated Trial:
Title: Precise quantification of episcleral venous flow rates in human subjects before and after netarsudil 0.02%: May 4^th (Oral session)

Independent Research:
Title: The Efficacy of Rhopressa in Lowering Intraocular Pressure in Patients with Secondary Glaucoma: May 3^rd (Poster)
Title: A comparative study on the efficacy of netarsudil versus brimonidine in eyes already being treated with anti-ocular hypertensive medication: May 4^th (Poster)
Title: The Efficacy of Netarsudil - Post-approval Reality: May 4^th (Poster)
Title: Tolerability and Persistence with Netarsudil Containing Regimens in Patients with Primary and Secondary Glaucomas: May 3^rd (Poster)
Title: Evaluation of various Rho-Associated Kinase (ROCK) inhibitors on the attachment and proliferation of primary corneal endothelial cells: May 3^rd (Poster)
Title: Topical netarsudil for the treatment of canine corneal endothelial degeneration: May 3^rd (Poster)
Title: Punctal stenosis associated with topical netarsudil use: May 4th (Poster)
Title: Effect of the Rho-kinase Inhibitor Netarsudil on Corneal Neovascularization in an Alkali-Burn Mouse Model: May 1^st (Poster)
Title: Effects of long-term application of topical ROCK inhibitor on corneal endothelium and Descemet’s membrane of TAZ deficient mice: May 3^rd (oral session)

About Aerie Pharmaceuticals, Inc.

Aerie is a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). Aerie’s first novel product, Rhopressa^® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage. More information about Rhopressa^®, including the product label, is available at www.rhopressa.com. Aerie’s second novel product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan^® (netarsudil (0.02%) and latanoprost ophthalmic solution (0.005%)), was launched in the United States in May 2019. In clinical trials of Rocklatan^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage. More information about Rocklatan^®, including the product label, is available at www.rocklatan.com. More information on Aerie Pharmaceuticals is available at www.aeriepharma.com.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “exploring,” “pursuing” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements in this release include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our commercial franchise and our pipeline, any guidance or timelines and our ongoing and anticipated preclinical studies and clinical trials. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, industry change and other factors beyond our control, and depend on regulatory approvals and economic and other environmental circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We discuss many of these risks in greater detail under the heading “Risk Factors” in the quarterly and annual reports that we file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220426006059/en/

Media:

Carolyn McAuliffe

cmcauliffe@aeriepharma.com

(949) 526-8733

Investors:

LifeSci Advisors on behalf of Aerie Pharmaceuticals, Inc.

Hans Vitzthum

hans@lifesciadvisors.com

(617) 430-7578

Source: Aerie Pharmaceuticals, Inc.

FAQ

What is Aerie Pharmaceuticals showcasing at ARVO 2022?

Aerie Pharmaceuticals is showcasing fourteen abstracts related to Rhopressa^®/netarsudil, AR-15512, and its ROCK’Sters program.

When is the ARVO 2022 meeting taking place?

The ARVO 2022 meeting is scheduled for May 1 through 4, 2022, in Denver, Colorado.

What is the significance of the AR-15512 for Aerie Pharmaceuticals?

AR-15512 is undergoing clinical trials to address dry eye symptoms, with positive Phase 2b results potentially bolstering its market value.

How does netarsudil relate to Aerie's research at ARVO 2022?

Netarsudil's research at ARVO 2022 includes independent studies and preclinical data that may broaden its clinical applications.

What are the implications of the research presented by Aerie Pharmaceuticals?

The research could enhance the credibility of Aerie's products and facilitate future development and marketing strategies.